| review article | Q7318358 |
| scholarly article | Q13442814 |
| systematic review | Q1504425 |
| P5530 | Altmetric DOI | 10.1186/S12885-017-3693-7 |
| P6179 | Dimensions Publication ID | 1092310847 |
| P356 | DOI | 10.1186/S12885-017-3693-7 |
| P953 | full work available at URL | http://eprints.whiterose.ac.uk/128063/ |
| P932 | PMC publication ID | 5654013 |
| P698 | PubMed publication ID | 29061138 |
| P1154 | Scopus EID | 2-s2.0-85031914389 |
| P50 | author | Jacqui A Shaw | Q61264525 |
| Angela Cox | Q28484012 | ||
| Orla Sheils | Q30348428 | ||
| P2093 | author name string | Ian A Cree | |
| Dawn Teare | |||
| Lesley Uttley | |||
| Susan Harnan | |||
| Michael Messenger | |||
| Helen Buckley Woods | |||
| Anne Reiman | |||
| Sian Taylor Philips | |||
| Becky L Whiteman | |||
| Hugh Kikuchi | |||
| UK Early Cancer Detection Consortium | |||
| P2860 | cites work | Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis | Q73121380 |
| Comparative analysis of mesenteric and peripheral blood circulating tumor DNA in colorectal cancer patients | Q79362867 | ||
| Elevated level of cell-free plasma DNA is associated with breast cancer | Q80152253 | ||
| Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA | Q80166978 | ||
| Levels of circulating cell-free serum DNA in benign and malignant breast lesions | Q80430527 | ||
| The detection of oesophageal adenocarcinoma by serum microsatellite analysis | Q83056034 | ||
| Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer | Q83264629 | ||
| CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer | Q83843096 | ||
| Quantitative measurement of cell-free plasma DNA and applications for detecting tumor genetic variation and promoter methylation in a clinical setting | Q84115839 | ||
| Noninvasive prenatal diagnosis: from dream to reality | Q85663657 | ||
| Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer | Q87567670 | ||
| Promoter hypermethylation of tumor suppressor genes in serum as potential biomarker for the diagnosis of nasopharyngeal carcinoma. | Q50888098 | ||
| Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients. | Q50981768 | ||
| Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum. | Q51140319 | ||
| Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients. | Q51600504 | ||
| Molecular Diagnostic of Prostate Cancer From Body Fluids Using Methylation-Specific PCR (MS-PCR) Method. | Q51610064 | ||
| Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. | Q51711228 | ||
| Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. | Q52876183 | ||
| Microsatellite analysis of induced sputum DNA in patients with lung cancer in heavy smokers and in healthy subjects. | Q53026019 | ||
| STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies. | Q53089122 | ||
| Prostate cancer molecular detection in plasma samples by glutathione S-transferase P1 (GSTP1) methylation analysis. | Q53237349 | ||
| Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. | Q53369810 | ||
| Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. | Q53527046 | ||
| Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. | Q53588084 | ||
| Improved sensitivity of circulating tumor DNA measurement using short PCR amplicons. | Q54182906 | ||
| Circulating free DNA in a screening program for early colorectal cancer detection. | Q54207521 | ||
| Quantification of plasma hTERT DNA in hepatocellular carcinoma patients by quantitative fluorescent polymerase chain reaction. | Q54356121 | ||
| Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients. | Q54394872 | ||
| Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. | Q54428093 | ||
| Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. | Q54578238 | ||
| Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. | Q54714698 | ||
| Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the Fetus | Q56937251 | ||
| Presence of fetal DNA in maternal plasma and serum | Q57075132 | ||
| Tumor Cell-SpecificBRCA1andRASSF1AHypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients | Q57240001 | ||
| Evaluation of cell-free DNA as a biomarker for pancreatic malignancies | Q57272448 | ||
| SHOX2 DNA Methylation Is a Biomarker for the Diagnosis of Lung Cancer in Plasma | Q58068480 | ||
| Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay | Q21090079 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| Cell-free DNA as a diagnostic marker for cancer: current insights | Q28074556 | ||
| Methylation of cell-free circulating DNA in the diagnosis of cancer | Q28085699 | ||
| Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer | Q28243334 | ||
| Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer | Q28390093 | ||
| Detection of circulating tumor DNA in early- and late-stage human malignancies | Q29615778 | ||
| Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer | Q33520078 | ||
| An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. | Q33590850 | ||
| Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. | Q33663019 | ||
| Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer | Q33808960 | ||
| Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma | Q33868284 | ||
| Improved blood tests for cancer screening: general or specific? | Q34086617 | ||
| Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer | Q34100603 | ||
| Detection and quantification of mutations in the plasma of patients with colorectal tumors | Q34132363 | ||
| Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. | Q34322575 | ||
| Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer | Q34354622 | ||
| Liquid biopsy: monitoring cancer-genetics in the blood | Q34356149 | ||
| Novel methylation biomarker panel for the early detection of pancreatic cancer | Q34374959 | ||
| Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors | Q34416049 | ||
| Guidance for laboratories performing molecular pathology for cancer patients | Q34431280 | ||
| Circulating tumor DNA as a liquid biopsy for cancer | Q34447436 | ||
| Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer | Q34500078 | ||
| A novel Alu-based real-time PCR method for the quantitative detection of plasma circulating cell-free DNA: sensitivity and specificity for the diagnosis of myocardial infarction | Q34599093 | ||
| Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA. | Q34744294 | ||
| Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA. | Q50533631 | ||
| Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. | Q50640273 | ||
| Plasma nucleic acids in the diagnosis and management of malignant disease. | Q34762682 | ||
| Detection of HER2 amplification in circulating free DNA in patients with breast cancer. | Q34806810 | ||
| Influence of plasma processing on recovery and analysis of circulating nucleic acids | Q35035846 | ||
| An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. | Q35091230 | ||
| Circulating tumour markers can define patients with normal colons, benign polyps, and cancers | Q35125657 | ||
| Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. | Q35127938 | ||
| Stage at diagnosis and early mortality from cancer in England. | Q35275282 | ||
| Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer | Q35392062 | ||
| Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas | Q35421479 | ||
| Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. | Q35723986 | ||
| DNA methylation patterns in blood of patients with colorectal cancer and adenomatous colorectal polyps | Q35785652 | ||
| Diagnostic value of SHOX2 DNA methylation in lung cancer: a meta-analysis | Q35861862 | ||
| Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma | Q35940554 | ||
| Cell-free DNA in blood is a potential diagnostic biomarker of breast cancer | Q35995351 | ||
| Methylation profiling of normal individuals reveals mosaic promoter methylation of cancer-associated genes | Q36050701 | ||
| Building the Evidence Base of Blood-Based Biomarkers for Early Detection of Cancer: A Rapid Systematic Mapping Review | Q36079639 | ||
| Quantitative analysis of cell-free DNA in ovarian cancer | Q36334715 | ||
| Tumor-Related Methylated Cell-Free DNA and Circulating Tumor Cells in Melanoma. | Q36443927 | ||
| Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation | Q36614162 | ||
| Circulating (cell-free) nucleic acids--a promising, non-invasive tool for early detection of several human diseases | Q36731622 | ||
| Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanoma | Q36804878 | ||
| Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening | Q36903459 | ||
| Differential methylation profile of ovarian cancer in tissues and plasma | Q37024691 | ||
| Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer | Q37109790 | ||
| Concentration and Methylation of Cell-Free DNA from Blood Plasma as Diagnostic Markers of Renal Cancer. | Q37306747 | ||
| Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer | Q37552649 | ||
| Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease | Q37580040 | ||
| Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: preliminary report | Q37677042 | ||
| From discovery to the clinic: the novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood | Q37961764 | ||
| Tumor markers in clinical practice: a review focusing on common solid cancers | Q38010046 | ||
| Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients | Q38023058 | ||
| Hypermethylated FAM5C and MYLK in serum as diagnosis and pre-warning markers for gastric cancer | Q38327308 | ||
| Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial | Q38385410 | ||
| Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system | Q38392527 | ||
| Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer | Q38418038 | ||
| Assessment of DNA Integrity, Applications for Cancer Research. | Q38558563 | ||
| Rapid Identification of Plasma DNA Samples with Increased ctDNA Levels by a Modified FAST-SeqS Approach. | Q38884073 | ||
| Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis | Q38993983 | ||
| A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. | Q39159559 | ||
| Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C? | Q39258541 | ||
| Commonality and differences of methylation signatures in the plasma of patients with pancreatic cancer and colorectal cancer | Q39305196 | ||
| Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules | Q40015475 | ||
| Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders | Q40229747 | ||
| Circulating free DNA as non-invasive diagnostic biomarker for childhood solid tumors | Q40315162 | ||
| A Comparison of Cell-Free DNA Isolation Kits: Isolation and Quantification of Cell-Free DNA in Plasma. | Q40421982 | ||
| Assessment of the total cfDNA and HPV16/18 detection in plasma samples of head and neck squamous cell carcinoma patients. | Q40826236 | ||
| Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies | Q41484128 | ||
| Detection of Clonal and Subclonal Copy-Number Variants in Cell-Free DNA from Patients with Breast Cancer Using a Massively Multiplexed PCR Methodology | Q41821680 | ||
| Epigenetic alteration: new insights moving from tissue to plasma - the example of PCDH10 promoter methylation in colorectal cancer. | Q42546251 | ||
| Cell-free DNA concentration and integrity as a screening tool for cancer | Q43502233 | ||
| Usefulness of plasma epigenetic changes of five major genes involved in the pathogenesis of colorectal cancer | Q43526081 | ||
| CST6 promoter methylation in circulating cell-free DNA of breast cancer patients | Q43599098 | ||
| Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study | Q43807211 | ||
| PAI-1, t-PA and circulating hTERT DNA as related to virus infection in liver carcinogenesis. | Q43866102 | ||
| Use of a new generation of capillary electrophoresis to quantify circulating free DNA in non-small cell lung cancer | Q44116681 | ||
| Detecting lung cancer in plasma with the use of multiple genetic markers | Q44656374 | ||
| Investigation of tumor-derived extracellular DNA in blood of cancer patients by methylation-specific PCR. | Q45160146 | ||
| Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies | Q45785843 | ||
| SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer | Q46393758 | ||
| Parallel assessment of circulatory cell-free DNA by PCR and nucleosomes by ELISA in breast tumors | Q46482013 | ||
| Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. | Q46622188 | ||
| Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool panel for early detection of thyroid cancer | Q47817610 | ||
| Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors | Q48292008 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neoplasm | Q1216998 |
| cell-free tumour DNA | Q19596321 | ||
| tumor biomarker | Q66205818 | ||
| early detection of cancer | Q66770492 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 697 | |
| P577 | publication date | 2017-10-23 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review | |
| P478 | volume | 17 |
| Q92655999 | A Machine Learning Method for Identifying Lung Cancer Based on Routine Blood Indices: Qualitative Feasibility Study |
| Q55517990 | A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA. |
| Q55692870 | Cancer Diagnosis Using a Liquid Biopsy: Challenges and Expectations. |
| Q91809276 | Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study |
| Q91742610 | Circulating tumor DNA in colorectal cancer: opportunities and challenges |
| Q90091304 | Comparison of Target Enrichment Platforms for Circulating Tumor DNA Detection |
| Q48216212 | Detection and localization of surgically resectable cancers with a multi-analyte blood test. |
| Q64121613 | Developing a blood-based gene mutation assay as a novel biomarker for oesophageal adenocarcinoma |
| Q94586263 | Hydroxymethylation and tumors: can 5-hydroxymethylation be used as a marker for tumor diagnosis and treatment? |
| Q94948707 | Identification of novel methylation markers in HPV-associated oropharyngeal cancer: genome-wide discovery, tissue verification and validation testing in ctDNA |
| Q93044719 | Liquid Biopsy in Colorectal Cancer-Current Status and Potential Clinical Applications |
| Q90322849 | Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology |
| Q92586446 | Multiplex methylated DNA testing in plasma with high sensitivity and specificity for colorectal cancer screening |
| Q64263563 | Oncosuppressor-Mutated Cells as a Liquid Biopsy Test for Cancer-Screening |
| Q47348974 | Panomics for Precision Medicine |
| Q98288342 | Potential of modern circulating cell-free DNA diagnostic tools for detection of specific tumour cells in clinical practice |
| Q92860780 | Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients |
| Q90724422 | Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy |
| Q98578577 | The International Collaboration for Cancer Classification and Research (IC3 R) |
| Q90464695 | Tracking cancer progression: from circulating tumor cells to metastasis |
| Q90079694 | Ultrasensitive DNA hypermethylation detection using plasma for early detection of NSCLC: a study in Chinese patients with very small nodules |
| Q97424206 | ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper |
Search more.